Department of Ophthalmology, College of Medicine, Konyang University, Daejeon, Korea.
Cornea. 2013 May;32(5):689-95. doi: 10.1097/ICO.0b013e3182801645.
To compare the effects of subconjunctival injection and topical application of bevacizumab and sunitinib on experimentally induced corneal neovascularization (CNV).
CNV was induced by sutures in the right eyes of 36 rabbits. After suture removal, the rabbits were divided into 6 groups with 6 rabbits in each group. In groups 1, 2, and 3, the eyes received a subconjunctival injection of 0.1 mL of normal saline, 2.5 mg/0.1 mL of bevacizumab, and 0.25 mg/0.1 mL of sunitinib, respectively, immediately after suture removal. A booster injection of the same agent was repeated 1 week later in each group. In groups 4, 5, and 6, the eyes received topical applications of saline, bevacizumab (5 mg/mL), and sunitinib (0.5 mg/mL), respectively. These solutions were applied twice a day for 2 weeks, starting immediately after suture removal. CNV was analyzed through biomicroscopy and through histological examination using hematoxylin and eosin and CD31 immunohistochemical staining.
On day 14, the mean percentages of areas of CNV in sunitinib-treated eyes were smaller compared with saline-treated or bevacizumab-treated eyes in both the subconjunctival (P = 0.003 and 0.032, respectively) and topical groups (P < 0.001 in both). The topical administration of sunitinib was significantly more effective than the subconjunctival injection of the same drug at 1 week (P = 0.011). Upon histological examination of samples from the topical group, sunitinib-treated eyes showed lower vascularity than saline-treated and bevacizumab-treated eyes (P = 0.036 and 0.046, respectively).
These results suggest that sunitinib is more effective than bevacizumab for the inhibition of CNV. Furthermore, topical administration of sunitinib yields better results than a subconjunctival injection of the same medication.
比较贝伐单抗和舒尼替尼经结膜下注射和局部应用对实验性诱导的角膜新生血管（CNV）的作用。
在 36 只兔子的右眼用缝线诱导 CNV。缝线去除后，将兔子分为 6 组，每组 6 只。在第 1、2 和 3 组中，缝线去除后立即用 0.1 mL 生理盐水、2.5 mg/0.1 mL 贝伐单抗和 0.25 mg/0.1 mL 舒尼替尼进行结膜下注射。每组在 1 周后重复相同药物的加强注射。在第 4、5 和 6 组中，缝线去除后立即用生理盐水、贝伐单抗（5 mg/mL）和舒尼替尼（0.5 mg/mL）进行每日 2 次的局部应用，持续 2 周。通过生物显微镜和苏木精和伊红以及 CD31 免疫组织化学染色进行 CNV 分析。
在第 14 天，与生理盐水处理或贝伐单抗处理的眼睛相比，舒尼替尼处理的眼睛的 CNV 区域的平均百分比在结膜下（P = 0.003 和 0.032）和局部（P < 0.001 在两者中）组均较小。在 1 周时，局部给予舒尼替尼比给予相同药物的结膜下注射更有效（P = 0.011）。在局部组的样本进行组织学检查时，与生理盐水处理和贝伐单抗处理的眼睛相比，舒尼替尼处理的眼睛显示出较低的血管生成（P = 0.036 和 0.046）。
这些结果表明，舒尼替尼抑制 CNV 的效果优于贝伐单抗。此外，与结膜下注射相同药物相比，局部给予舒尼替尼的效果更好。
